Akamai Technologies (AKAM) Ownership Increased by Baird Financial Group, Inc

Akamai Technologies Inc

(AKAM) most recent 13F filing, the company has 53 new institutional holders - accounting for 3.07 million shares of its common stock. SunTrust Banks also issued estimates for Akamai Technologies' Q4 2017 earnings at $0.46 EPS, Q3 2018 earnings at $0.47 EPS, Q4 2018 earnings at $0.56 EPS and FY2018 earnings at $1.84 EPS.

Akamai Technologies (NASDAQ:AKAM) last announced its quarterly earnings data on Tuesday, October 24th.

Market capitalization is the total market value of all of a company's outstanding shares. The business had revenue of $584.10 million for the quarter, compared to analysts' expectations of $571.92 million. Enterprise Finance has invested 0.01% in Akamai Technologies, Inc. During the same quarter in the prior year, the firm earned $0.68 earnings per share.

Akamai Technologies, Inc. (NASDAQ:AKAM) tumbled -18.63% year-to-date. If you are viewing this news story on another website, it was copied illegally and reposted in violation of USA & global trademark and copyright law.

APG Asset Management N.V. reduced its position in Akamai Technologies, Inc.


AKAM has been the topic of several other reports. Cowen and Company reiterated a "hold" rating and set a $61.00 price objective on shares of Akamai Technologies in a research report on Friday, July 21st. Fairpointe Capital Llc acquired 981,069 shares as Akamai Technologies (AKAM)'s stock declined 24.00%. The rating was maintained by B. Riley & Co with "Buy" on Wednesday, October 25. Finally, Vetr downgraded shares of Akamai Technologies from a "strong-buy" rating to a "buy" rating and set a $52.07 price objective on the stock.in a research report on Wednesday, September 13th. Wells Fargo & Co. restated an "outperform" rating and set a $77.00 price target (up from $73.00) on shares of Akamai Technologies in a report on Wednesday, December 21st. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the company's stock.

In the market the company is trading up since yesterday's close of 53.52. The stock had a trading volume of 1,682,700 shares, compared to its average volume of 2,179,156. Akamai Technologies now has a P/E ratio of 32.12 and the market cap is 9.08B. Akamai Technologies has a 1 year low of $44.65 and a 1 year high of $71.64. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.20. First Trust Advisors LP lifted its position in shares of Akamai Technologies by 2.3% in the third quarter. Following the completion of the transaction, the director now owns 60,489 shares of the company's stock, valued at $4,101,759.09. The institutional investor held 10,775 shares of the miscellaneous company at the end of 2017Q2, valued at $537,000, down from 16,980 at the end of the previous reported quarter. Janus Henderson Group PLC grew its position in shares of Akamai Technologies by 5,158.8% in the second quarter. Raymond James & Associates now owns 293,984 shares valued at $14,323,000. (NASDAQ:AKAM) news were published by: Fool.com which released: "Why Akamai Technologies, NuVasive, and MacroGenics Jumped Today" on October 25, 2017, also Investorplace.com with their article: "Akamai Technologies, Inc". Advisory Services Network LLC now owns 2,025 shares of the technology infrastructure company's stock valued at $101,000 after buying an additional 168 shares during the period. Sumitomo Mitsui Asset Management Company LTD raised its position in Akamai Technologies by 1.7% in the second quarter.

Akamai Technologies, Inc. (AKAM) has an annual dividend of $0, while its annual dividend yield is 0%. The stock was sold at an average price of $49.81, for a total value of $498,100.00.

The most recent non open market insider trade was completed by LEIGHTON F THOMSON on 07/14/2017, and was a acquisition of 19,817 shares with a final price of $50.45. The share price has yet to cross its 20 days moving average, floating at a distance of -7.49% and sits -13.99% lower versus its 50 days moving average. Balyasny Asset Mngmt Limited Liability owns 0.02% invested in Array Biopharma Inc (NASDAQ:ARRY) for 719,124 shares. The disclosure for this purchase can be found here. On average, equities research analysts anticipate that Akamai Technologies will post $2.67 earnings per share for the current fiscal year.

Related:

Comments

Latest news

Ex-CIA Director Claims Trump Scared Of Putin
James Clapper , the former director of national intelligence, called the threat from Russian Federation "manifest and obvious". He wants to have a good relationship with Putin, not argue about the election but work on Syria and North Korea and Ukraine.

Argentina to host 2023 World Expo
Mark Dayton commended the Minnesota team that organized the bid. Minnesota was in a three-way battle with Poland and Argentina. Before the vote was announced, Gov.

Lil Peep Dies at 21
The rising 21-year-old singer and rapper died at the age of 21 , as reported by Billboard early on Thursday morning (November 16).

Russia Found Still Not Complying On Doping, Hurting Olympic Hopes
He noted that the unqualified acceptance of the findings of the Board Richard McLaren on doping in Russian sport impossible. It's unclear how this will affect athletes heading into the 2018 Games.

The Weeknd in touch with Bella Hadid
Raisa donated her kidney to Gomez in September, and she wants nothing but the best for her good friend. Gomez was treated for depression a few years back. "He also apologised for hurting her in the past".

Other news